Skip to main content
Erschienen in: Medical Oncology 7/2014

01.07.2014 | Original Paper

Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population

verfasst von: Katarzyna Starska, Anna Krześlak, Ewa Forma, Jurek Olszewski, Iwona Lewy-Trenda, Ewa Osuch-Wójcikiewicz, Magdalena Bryś

Erschienen in: Medical Oncology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Metallothioneins are intracellular regulators of many biological mechanisms including differentiation, proliferation, angiogenesis and invasion, which are crucial processes in carcinogenesis. This study examines the association between three single-nucleotide polymorphisms at loci −5 A/G (rs28366003) and −209 A/G (rs1610216) in the core promoter region and at locus +838 C/G (rs10636) in 3′UTR region of the metallothionein 2A (MT2A) gene with squamous cell laryngeal cancer (SCLC) risk, as well as with tumor invasiveness according to tumor front grading (TFG). Genotyping was performed using the polymerase chain reaction–restriction fragment length polymorphism technique in 323 genetically unrelated individuals with SCLC and 418 randomly selected healthy volunteers. Only one SNP (rs28366003) was significantly related to laryngeal cancer in the study population. Compared with homozygous common allele carriers, heterozygous and homozygous for the G variant had significantly increased risk of SCLC [adjusted odds ratio (OR) = 2.90, 95 % confidence interval (CI) 1.53–5.21, p dominant < 0.001]. The A/G allele carriers at rs28366003 MT2A were at higher risk of SCLC development (OR = 2.63, 95 % CI 1.41–2.85, p < 0.001]. There was a significant association between the rs28366003 and stage and TFG classification. Most carriers of minor allele had a higher stage (OR = 2.76, 95 % CI 1.11–7.52, p = 0.03), increased cancer aggressiveness, as defined by a higher total TFG score (>18 points) (OR = 3.76, 95 % CI 1.15–12.56, p = 0.03) and diffuse tumor growth (OR = 5.86, 95 % Cl 0.72–44.79, p = 0.08). The results of this study raise a possibility that a genetic variation of MT2A may be implicated in the etiology of laryngeal cancer in a Polish population.
Literatur
1.
Zurück zum Zitat Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, Adam V, Kizek R, Masarik M. Metallothionein polymorphisms in pathological processes. Metallomics. 2014;6(1):55–68.PubMedCrossRef Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, Adam V, Kizek R, Masarik M. Metallothionein polymorphisms in pathological processes. Metallomics. 2014;6(1):55–68.PubMedCrossRef
3.
Zurück zum Zitat Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L, Skutkova H, Provaznik I, Hubalek J, Kizek R. Mammalian metallothioneins: properties and functions. Metallomics. 2012;4(8):739–50.PubMedCrossRef Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L, Skutkova H, Provaznik I, Hubalek J, Kizek R. Mammalian metallothioneins: properties and functions. Metallomics. 2012;4(8):739–50.PubMedCrossRef
4.
Zurück zum Zitat Mehus AA, Muhonen WW, Garrett SH, Somji S, Sens DA, Shabb JB. Quantitation of human metallothionein isoforms: a family of small, highly conserved cysteine-rich proteins. Mol Cell Proteomics. 2014;13(4):1020–33.PubMedCrossRef Mehus AA, Muhonen WW, Garrett SH, Somji S, Sens DA, Shabb JB. Quantitation of human metallothionein isoforms: a family of small, highly conserved cysteine-rich proteins. Mol Cell Proteomics. 2014;13(4):1020–33.PubMedCrossRef
5.
Zurück zum Zitat Juang HH, Chung LC, Sung HC, Feng TH, Lee YH, Chang PL, Tsui KH. Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate. 2013;73(14):1495–506.PubMedCrossRef Juang HH, Chung LC, Sung HC, Feng TH, Lee YH, Chang PL, Tsui KH. Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate. 2013;73(14):1495–506.PubMedCrossRef
6.
Zurück zum Zitat Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009;44:29–64.PubMedCrossRef Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009;44:29–64.PubMedCrossRef
7.
Zurück zum Zitat Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. J Transl Med. 2013;11:173. doi:10.1186/1479-5876-11-173.PubMedCentralPubMedCrossRef Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. J Transl Med. 2013;11:173. doi:10.​1186/​1479-5876-11-173.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, Adam V, Kizek R, Stiborova M, Masarik M. Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 2014;44(3):923–33.PubMed Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, Adam V, Kizek R, Stiborova M, Masarik M. Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 2014;44(3):923–33.PubMed
10.
11.
Zurück zum Zitat Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegiel P. Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res. 2013;33(12):5375–83.PubMed Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegiel P. Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res. 2013;33(12):5375–83.PubMed
12.
Zurück zum Zitat Forma E, Krześlak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a polish population. Cancer Genet. 2012;205:432–5.PubMedCrossRef Forma E, Krześlak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a polish population. Cancer Genet. 2012;205:432–5.PubMedCrossRef
13.
Zurück zum Zitat Krześlak A, Forma E, Jóźwiak P, Szymczyk A, Smolarz B, Romanowicz-Makowska H, Różański W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Exp Med. 2014;14(1):107–13.PubMedCentralPubMedCrossRef Krześlak A, Forma E, Jóźwiak P, Szymczyk A, Smolarz B, Romanowicz-Makowska H, Różański W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Exp Med. 2014;14(1):107–13.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Krześlak A, Forma E, Chwatko G, Jóźwiak P, Szymczyk A, Wilkosz J, Różański W, Bryś M. Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer. Toxicol Appl Pharmacol. 2013;268:278–85.PubMedCrossRef Krześlak A, Forma E, Chwatko G, Jóźwiak P, Szymczyk A, Wilkosz J, Różański W, Bryś M. Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer. Toxicol Appl Pharmacol. 2013;268:278–85.PubMedCrossRef
15.
Zurück zum Zitat Kita K, Miura M, Yoshida M, Yamazaki K, Ohkubo T, Imai Y, Naganuma A. Potential effect on cellular response to cadmium of a single-nucleotide A –>G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet. 2006;120:553–60.PubMedCrossRef Kita K, Miura M, Yoshida M, Yamazaki K, Ohkubo T, Imai Y, Naganuma A. Potential effect on cellular response to cadmium of a single-nucleotide A –>G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet. 2006;120:553–60.PubMedCrossRef
16.
Zurück zum Zitat Kayaaltı Z, Aliyev V, Söylemezoğlu T. The potential effect of metallothionein 2A–5 A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol Appl Pharmacol. 2011;256:1–7.PubMedCrossRef Kayaaltı Z, Aliyev V, Söylemezoğlu T. The potential effect of metallothionein 2A–5 A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol Appl Pharmacol. 2011;256:1–7.PubMedCrossRef
17.
Zurück zum Zitat Kayaalti Z, Mergen G, Söylemezoğlu T. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol Appl Pharmacol. 2010;245:252–5.PubMedCrossRef Kayaalti Z, Mergen G, Söylemezoğlu T. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol Appl Pharmacol. 2010;245:252–5.PubMedCrossRef
19.
Zurück zum Zitat Brazão-Silva MT, Cardoso SV, de Faria PR, Dias FL, Lima RA, Eisenberg AL, Nascimento MF, Loyola AM. Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour. Histopathology. 2013;63(6):802–9.PubMedCrossRef Brazão-Silva MT, Cardoso SV, de Faria PR, Dias FL, Lima RA, Eisenberg AL, Nascimento MF, Loyola AM. Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour. Histopathology. 2013;63(6):802–9.PubMedCrossRef
20.
Zurück zum Zitat Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, Point D, Tsourouflis G, Sastre-Garau X. Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patient survival. Histopathology. 2011;59:514–25.PubMedCrossRef Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, Point D, Tsourouflis G, Sastre-Garau X. Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patient survival. Histopathology. 2011;59:514–25.PubMedCrossRef
21.
Zurück zum Zitat Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, Zabel M. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res. 2007;27:335–42.PubMed Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, Zabel M. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res. 2007;27:335–42.PubMed
22.
Zurück zum Zitat Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRef Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRef
23.
Zurück zum Zitat Starska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006;51:200–4.PubMed Starska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006;51:200–4.PubMed
24.
Zurück zum Zitat Qiao X, Ma ZY, Shao J, Bao WG, Xu JY, Qiang ZY, Lou JS. Biological evaluation of a cytotoxic 2-substituted benzimidazole copper (II) complex: DNA damage, antiproliferation and apoptotic induction activity in human cervical cancer cells. Biometals. 2014;27:155–72.PubMedCrossRef Qiao X, Ma ZY, Shao J, Bao WG, Xu JY, Qiang ZY, Lou JS. Biological evaluation of a cytotoxic 2-substituted benzimidazole copper (II) complex: DNA damage, antiproliferation and apoptotic induction activity in human cervical cancer cells. Biometals. 2014;27:155–72.PubMedCrossRef
25.
Zurück zum Zitat Tokar EJ, Benbrahim-Tallaa L, Waalkes MP. Metal ions in human cancer development. Met Ions Life Sci. 2011;8:375–401.PubMed Tokar EJ, Benbrahim-Tallaa L, Waalkes MP. Metal ions in human cancer development. Met Ions Life Sci. 2011;8:375–401.PubMed
27.
Zurück zum Zitat Kayaaltı Z, Sahiner L, Durakoğlugil ME, Söylemezoğlu T. Distributions of interleukin-6 (IL-6) promoter and metallothionein 2A (MT2A) core promoter region gene polymorphisms and their associations with aging in Turkish population. Arch Gerontol Geriatr. 2011;53(3):354–8.PubMedCrossRef Kayaaltı Z, Sahiner L, Durakoğlugil ME, Söylemezoğlu T. Distributions of interleukin-6 (IL-6) promoter and metallothionein 2A (MT2A) core promoter region gene polymorphisms and their associations with aging in Turkish population. Arch Gerontol Geriatr. 2011;53(3):354–8.PubMedCrossRef
28.
Zurück zum Zitat Kayaalti Z, Söylemezoğlu T. The polymorphism of core promoter region on metallothionein 2A-metal binding protein in Turkish population. Mol Biol Rep. 2010;37(1):185–90.PubMedCrossRef Kayaalti Z, Söylemezoğlu T. The polymorphism of core promoter region on metallothionein 2A-metal binding protein in Turkish population. Mol Biol Rep. 2010;37(1):185–90.PubMedCrossRef
29.
Zurück zum Zitat Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy? Breast. 2013;22(5):817–23.PubMedCrossRef Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy? Breast. 2013;22(5):817–23.PubMedCrossRef
30.
Zurück zum Zitat Seibold P, Hein R, Schmezer P, Hall P, Liu J, Dahmen N, Flesch-Janys D, Popanda O, Chang-Claude J. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer. 2011;129:1467–76.PubMedCrossRef Seibold P, Hein R, Schmezer P, Hall P, Liu J, Dahmen N, Flesch-Janys D, Popanda O, Chang-Claude J. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer. 2011;129:1467–76.PubMedCrossRef
31.
Zurück zum Zitat McElroy JA, Bryda EC, McKay SD, Schnabel RD, Taylor JF. Genetic variation at a metallothionein 2A promoter single-nucleotide polymorphism in white and black females in Midwestern United States. J Toxicol Environ Health. 2010;73:1283–7.CrossRef McElroy JA, Bryda EC, McKay SD, Schnabel RD, Taylor JF. Genetic variation at a metallothionein 2A promoter single-nucleotide polymorphism in white and black females in Midwestern United States. J Toxicol Environ Health. 2010;73:1283–7.CrossRef
32.
Zurück zum Zitat Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009;35(3):477–83.PubMed Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009;35(3):477–83.PubMed
33.
Zurück zum Zitat Tekin D, Kayaaltı Z, Söylemezoğlu T. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels? Int Arch Occup Environ Health. 2012;85(6):631–7.PubMedCrossRef Tekin D, Kayaaltı Z, Söylemezoğlu T. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels? Int Arch Occup Environ Health. 2012;85(6):631–7.PubMedCrossRef
34.
Zurück zum Zitat Gansukh T, Donizy P, Halon A, Lage H, Surowiak P. In vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells. Anticancer Res. 2013;33:5255–60.PubMed Gansukh T, Donizy P, Halon A, Lage H, Surowiak P. In vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells. Anticancer Res. 2013;33:5255–60.PubMed
35.
Zurück zum Zitat Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett. 2005;26:567–74.PubMed Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett. 2005;26:567–74.PubMed
37.
Zurück zum Zitat Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M, Jankowska R, Dziegiel P. Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol. 2013;94(1):301–8.PubMedCrossRef Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M, Jankowska R, Dziegiel P. Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol. 2013;94(1):301–8.PubMedCrossRef
Metadaten
Titel
Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population
verfasst von
Katarzyna Starska
Anna Krześlak
Ewa Forma
Jurek Olszewski
Iwona Lewy-Trenda
Ewa Osuch-Wójcikiewicz
Magdalena Bryś
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 7/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0075-8

Weitere Artikel der Ausgabe 7/2014

Medical Oncology 7/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.